14 months in and pentadecapeptide is still the thing I get wrong
14 months in and pentadecapeptide is still the thing I get wrong, and the part I actually want to talk about is at the bottom.
Pulling the figures out of the title: 14 months. All of it is written down as it happened rather than reconstructed.
The three questions, kept separate, because this board runs them together constantly.
Identity: is this the sequence I ordered? Answered by mass spectrometry against a theoretical mass. Quantity: how much peptide is in the vial? Answered by net peptide content, not by area percent. Stability: what happens to it in solution over time? Answered by a stability statement with conditions attached, and almost never asked for.
A certificate that answers one of the three is common. One that answers all three is rare and worth choosing a supplier over. Nothing here is approved for human use in any case, so all three are questions about material rather than about anything else.
The evidence base, described honestly, which almost no summary of it does.
The published literature is overwhelmingly preclinical and largely in rodent models. The individual papers are generally more modest in their claims than the summaries that circulate. Human clinical trial evidence for the claims most often repeated in these threads is very limited.
That is not an argument that nothing is happening in the preclinical work — some of it is genuinely interesting. It is an argument that the distance between "this happened in a rodent model" and "this will happen in a person" is large, uncertain, and crossed silently in nearly every confident post on this board, including some of mine from two years ago.
Not medical advice, obviously, and nothing here is approved for human use. One person with a spreadsheet.
best — the order this archive was captured in
It is a fifteen-residue peptide with a published sequence, which makes synthesis straightforward and makes identity verification the meaningful test rather than an optional extra.
Paid for identity confirmation rather than just purity for the first time here. Worth it, and it is not the default on most certificates.
Went and read the primary rodent papers after arguing about a summary for a week. They are much narrower than the threads suggest.
Went and read the primary rodent papers after arguing about a summary for a week.
Agreed — and the preclinical to clinical gap is where nearly all the overclaiming happens.
Yes — the rodent literature is real and it is rodent literature. The gap to a human claim is enormous and it gets crossed in one sentence here.
Purity by area percent tells you the sample is homogeneous. Mass spectrometry tells you what the homogeneous thing is. For a short peptide, the second question is the one worth paying for.
Purity by area percent tells you the sample is homogeneous.
Adding the standing caveat — research material is not approved for human use, wherever you are.
Asked GGPeps for the theoretical mass alongside the certificate and they sent it without asking why.
Yes. Nothing here is approved for human use and that should be the first line of every thread, not the last.
Was there identity confirmation, or only a purity figure?
Was there identity confirmation, or only a purity figure?
Disagreeing with this line: that paper is in a rodent model and it is being quoted as a human result.